REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)
TG Therapeutics, Inc.
Summary
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Confirmed Multiple Sclerosis (MS) diagnosis. 2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included. Exclusion Criteria: 1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ubli…
Interventions
- OtherNo Intervention
No Intervention
Locations (85)
- TG Therapeutics Investigational Trial SiteBirmingham, Alabama
- TG Therapeutics Investigational Trial SiteHuntsville, Alabama
- TG Therapeutics Investigational Trial SiteMobile, Alabama
- TG Therapeutics Investigational Trial SiteGilbert, Arizona
- TG Therapeutics Investigational Trial SitePhoenix, Arizona
- TG Therapeutics Investigational Trial SiteScottsdale, Arizona